AGM
HQL

Alpine Global Management’s abrdn Life Sciences Investors HQL Stock Holding History

Alpine Global Management’s Portfolio HQL Stock Details HQL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-25,699
Closed -$437K – 320
2016
Q4 		$437K Buy
+25,699
New +$451K 0.2% 84

Other funds holding HQL

NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
FHA
Flagship Harbor Advisors Boston, Massachusetts $2.27B AUM 18.34% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Bank of Nova Scotia
Bank of Nova Scotia Toronto, Ontario, Canada $57.2B AUM 35.3% 1-Year Est. Return
Cohen & Steers
Cohen & Steers New York $57.6B AUM 8.03% 1-Year Est. Return

Alpine Global Management's HQL Position: Q1 2017 in Review

Alpine Global Management sold out of abrdn Life Sciences Investors (HQL) in Q1 2017, closing a stake of 25,699 shares — an estimated $437K sold.

Alpine Global Management first reported a position in HQL in Q4 2016 and held it in 1 quarter. The position peaked at $437K in Q4 2016. 41 funds tracked by Wall St. Rank hold HQL as of Q1 2017.

  • Alpine Global Management reported no remaining abrdn Life Sciences Investors position as of Q1 2017 after selling out during the quarter.
  • Alpine Global Management sold 25,699 abrdn Life Sciences Investors shares in Q1 2017, an estimated $437K.
  • Alpine Global Management first reported a position in abrdn Life Sciences Investors in Q4 2016 and held it in 1 quarter.
  • Alpine Global Management's abrdn Life Sciences Investors position peaked at $437K in Q4 2016.
  • 41 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q1 2017.

Based on Alpine Global Management's 13F filing for Q1 2017, filed 15 May 2017.